6
Jan
2026

Variant Bio Attracts Boehringer With AI Discovery of Kidney Disease Targets

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.

You may also like

Variant Bio Strikes New Pharma Bargain, Shares Benefits of Human Genetic Research
Medicines Based on Unusual Genetic Traits: Andrew Farnum on The Long Run